Table 2. Clinical characteristics of PTDM and non-PTDM subjects.

Baseline characteristics	PTDM (n = 42)	non-PTDM (n = 98)	p value
Males / Females	0/12	75/23	0.001
Age:
a) Males (Mean ± SD)	39.39 ± 12.12	39.55 ± 10.58	0.27
b) Females (Mean ± SD)	40.01 ± 11.63	39.26 ± 10.87	0.58
Weight:
a) Males (Mean ± SD)	62.73 ± 15.81	66.03 ±12.73	0.08
b) Females (Mean± SD)	61.71 ± 16.93	65.49 ± 13.68	0.09
Therapy:
a) On CsA therapy	22	58	0.01
b) On Tac therapy	20	40	0.02
Dose:
a) CsA Dose (mg)	163.88 ± 57.4	201.29 ± 76.86	0.03
b) Tac Dose (mg)	3.15 ± 1.24	3.11 ± 1.62	0.05
Levels:
a) C2 levels (ng/mL) CsA	750 ± 299.03	1024.8 ± 353.42	0.23
b) Trough levels (ng/mL) Tac	9.55 ± 3.38	8.0 ± 3.32	0.86
Levels:
a) C2 levels/dose of CsA	5.24 ± 2.59	5.52 ± 1.97	0.02
b) Trough levels/dose of Tac	3.62 ± 1.96	2.98 ± 1.49	0.02